Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 6;12(13):4516.
doi: 10.3390/jcm12134516.

Anti-Phospholipid Antibodies in Women with Placenta-Mediated Complications Delivered at >34 Weeks of Gestation

Uri Amikam  1   2 , Alyssa Hochberg  2   3 , Michael Shenhav  1   2 , Lilian Haj  2 , Sarit Hochberg-Klein  4 , Liran Hiersch  1   2 , Yariv Yogev  1   2
Affiliations

Anti-Phospholipid Antibodies in Women with Placenta-Mediated Complications Delivered at >34 Weeks of Gestation

Uri Amikam et al. J Clin Med. .

Abstract

Objective: To determine the prevalence of positive antiphospholipid (aPL) antibodies among pregnant women with placenta-mediated complications delivered at >340/7 weeks of gestation.

Methods: This was a single-center retrospective observational study conducted between 2017 and 2022. Inclusion criteria included pregnant or post-partum women, >18 years, diagnosed with any of the following placenta-mediated complications and delivered at >340/7 weeks of gestation: small-for-gestational-age neonate (SGA ≤ 5th percentile according to local birthweight charts), preeclampsia with severe features, and placental abruption. The primary outcome was the prevalence of positive aPL antibodies: Lupus anticoagulant, Anticardiolipin, or Anti-ß2glycoprotein1.

Results: Overall, 431 women met the inclusion criteria. Of them, 378(87.7%) had an SGA neonate, 30 had preeclampsia with severe features (7%), 23 had placental abruption (5.3%), and 21 patients had multiple diagnoses(4.9%). The prevalence of aPL antibodies in the cohort was 4.9% and was comparable between the three subgroups (SGA-3.9%; PET with severe features-3.3%; and placental abruption-13% (p = 0.17)).

Conclusion: aPL antibodies prevalence in women with placenta-mediated complications > 34 weeks of gestation was 4.9%, with comparable prevalence rates among the three subgroups. Future prospective studies are needed to delineate the need for treatment in those who tested positive for aPL antibodies and do not meet Anti-Phospholipid Antibody Syndrome clinical criteria.

Keywords: antiphospholipid antibodies; placental abruption; placental-mediated complications; preeclampsia; small-for-gestational-age.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of the study population. * 16 patients had multiple classifications. ** 5 patients had multiple classifications. Abbreviations: US—ultrasound; SGA—small-for-gestational-age; PET—preeclampsia.
See this image and copyright information in PMC

References

    1. Alijotas-Reig J., Esteve-Valverde E., Ferrer-Oliveras R., Sáez-Comet L., Lefkou E., Mekinian A., Belizna C., Ruffatti A., Tincani A., Marozio L., et al. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. Autoimmun. Rev. 2019;18:406–414. doi: 10.1016/j.autrev.2018.12.006. - DOI - PubMed
    1. Wilson W.A., Gharavi A.E., Koike T., Lockshin M.D., Branch D.W., Piette J.-C., Brey R., Derksen R., Harris E.N., Hughes G.R.V., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshop. Arthritis Rheum. 1999;42:1309–1311. doi: 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F. - DOI - PubMed
    1. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., Derksen R.H.W.M., De Groot P.G., Koike T., Meroni P.L., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J. Thromb. Haemost. 2006;4:295–306. doi: 10.1111/j.1538-7836.2006.01753.x. - DOI - PubMed
    1. Sciascia S., Amigo M.-C., Roccatello D., Khamashta M. Diagnosing antiphospholipid syndrome: ‘extra-criteria’ manifestations and technical advances. Nat. Rev. Rheumatol. 2017;13:548–560. doi: 10.1038/nrrheum.2017.124. - DOI - PubMed
    1. de Jesus G.R., Agmon-Levin N., Andrade C.A., Andreoli L., Chighizola C.B., Porter T.F., Salmon J., Silver R.M., Tincani A., Branch D.W. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome. Autoimmun. Rev. 2014;13:795–813. doi: 10.1016/j.autrev.2014.02.003. - DOI - PubMed

LinkOut - more resources